This study is in progress, not accepting new patients
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Summary
- Eligibility
- for people ages 12-17 (full criteria)
- Location
- at UC Davis UCSD
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Amgen
- Links
- AmgenTrials clinical trials website
- ID
- NCT05704738
- Phase
- Phase 3 Atopic Dermatitis (Eczema) Research Study
- Study Type
- Interventional
- Participants
- About 532 people participating
- Last Updated